Antiphospholipids antibodies and migraine
AbstractBackground: Antiphospholipids antibodies has been associated with non-thrombotic neurological conditions such as migraine. We set out to estimate the concentration of antiphospholipids antibody among patients with migraine and normal population. Methods: This is prospective case-control study of 158 subjects including 82 migraine patients who fulfilled the International Headache Society criteria for the diagnosis of migraine headache and 76 age and sex-matched controls who were mostly hospital staff and medical students. Blood samples
were taken for quantification of antiphospholipids antibodies.
Results: There were 28 males and 54 females among the migraine patients and 30 males and 46 females among the controls. Their mean ages were 28.8 + 8.4 years and 26.4 + 3.9 years, respectively. Migraine patients had increased level of aPL (lgG anti β2GP1) 27.76 + 14.47IU/ml compared to the normal healthy adults (21.43 + 9.4IU/ml) (p<0.05). Similarly, antiphospholipid antibodies was significantly elevated in migraine patients with aura compared to those without aura,
(2=0.037; p<0.05). The frequency of migraine attacks correlated positively with the concentration of lgG anti β2GP1; ( p<0.05).
Conclusion: We demonstrated increased serum level of lgG anti β2GP1 among migraine patients. The frequency of migraine attacks correlated positively with the concentration of lgG anti β2GP1.